Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances Collichio

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Cardiovascular and Interventional Radiology|January 15, 2021
Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary ExperienceLauren M B Burke, Hyeon Yu, Kaleigh Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Oncology fellows’ career plans, expectations, and well-being: do fellows know what they are getting into?Tait D Shanafelt, Marilyn Raymond, Leora Horn, et al.
Clinical Breast Cancer|September 1, 2006
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamideHanna Kelly, Gretchen Kimmick, E Claire Dees, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2008
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsE Claire Dees, Bert H O'Neil, Celeste M Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesLisa A Carey, E Claire Dees, Lynda Sawyer, et al.
Journal of the American College of Surgeons|January 29, 2019
Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional ExperienceRaphael J Louie, Matthew C Perez, Mohammad Raheel Jajja, et al.
Journal of the National Cancer Institute|August 4, 2005
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeLisa A Carey, Richard Metzger, E Claire Dees, et al.
Journal of Palliative Medicine|July 25, 2017
Integrating Palliative and Oncology Care for Patients with Advanced Cancer: A Quality Improvement InterventionLaura C Hanson, Frances Collichio, Stephen A Bernard, et al.
Annals of Surgical Oncology|June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialRobert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 28, 2023
Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapyJacob Hall, Kevin Lui, Xianming Tan, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cardiovascular and Interventional Radiology|January 15, 2021
Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary ExperienceLauren M B Burke, Hyeon Yu, Kaleigh Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Oncology fellows’ career plans, expectations, and well-being: do fellows know what they are getting into?Tait D Shanafelt, Marilyn Raymond, Leora Horn, et al.
Clinical Breast Cancer|September 1, 2006
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamideHanna Kelly, Gretchen Kimmick, E Claire Dees, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2008
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsE Claire Dees, Bert H O'Neil, Celeste M Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesLisa A Carey, E Claire Dees, Lynda Sawyer, et al.
Journal of the American College of Surgeons|January 29, 2019
Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional ExperienceRaphael J Louie, Matthew C Perez, Mohammad Raheel Jajja, et al.
Journal of the National Cancer Institute|August 4, 2005
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeLisa A Carey, Richard Metzger, E Claire Dees, et al.
Journal of Palliative Medicine|July 25, 2017
Integrating Palliative and Oncology Care for Patients with Advanced Cancer: A Quality Improvement InterventionLaura C Hanson, Frances Collichio, Stephen A Bernard, et al.
Annals of Surgical Oncology|June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialRobert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 28, 2023
Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapyJacob Hall, Kevin Lui, Xianming Tan, et al.
Pageof 3